Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 252 Breast Neoplasms 197 Glioblastoma 196 Lung Neoplasms 195 Head and Neck Neoplasms 176 Squamous Cell Carcinoma of Head and Neck 166 Prostatic Neoplasms 164 Lymphoma 152 Rectal Neoplasms 132 Central Nervous System Neoplasms 119 Esophageal Neoplasms 117 Leukemia 111 Brain Neoplasms 100 Pancreatic Neoplasms 95 Precursor Cell Lymphoblastic Leukemia-Lymphoma 93 Gliosarcoma 86 Esophageal Squamous Cell Carcinoma 83 Lymphoma, Follicular 81 Sarcoma 80 Lymphoma, Large B-Cell, Diffuse 80 Uterine Cervical Neoplasms 76 Lymphoma, Non-Hodgkin 75 Hodgkin Disease 73 Neoplasms 68 Burkitt Lymphoma 67 Leukemia, Lymphocytic, Chronic, B-Cell 63 Colorectal Neoplasms 63 Glioma 61 Astrocytoma 60 Lymphoma, Large-Cell, Immunoblastic 58

Interventions

Nivolumab 3 Cisplatin 2 Albumin-Bound Paclitaxel 2 tislelizumab 1 spartalizumab 1 Taxes 1 Standard of Care 1 Radiotherapy 1 Immunotherapy 1 Gemcitabine 1 130-nm albumin-bound paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Muscle-Invasive Bladder Carcinoma × Radiotherapy × Clear all

NCT05203913 2024-10-04

CNN-BC

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Phase 2 Recruiting

Muscle-Invasive Bladder Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡